TIAA CREF Investment Management’s Standard BioTools LAB Stock Holding History

TIAA CREF Investment Management’s Portfolio LAB Stock Details LAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	$1.85M	Buy	139,397 +70,793	+103%	+$746K	﹤0.01%	2042
2018 Q4	$591K	Buy	68,604 +11,400	+20%	+$88.8K	﹤0.01%	2501
2018 Q3	$428K	Sell	57,204 -20,978	-27%	-$149K	﹤0.01%	2780
2018 Q2	$466K	Sell	78,182 -7,739	-9%	-$44.1K	﹤0.01%	2811
2018 Q1	$502K	Hold	85,921	–	–	﹤0.01%	2734
2017 Q4	$506K	Buy	85,921 +9,442	+12%	+$51.7K	﹤0.01%	2766
2017 Q3	$385K	Sell	76,479 -3,258	-4%	-$13.7K	﹤0.01%	2935
2017 Q2	$322K	Buy	79,737 +30	+0%	+$142	﹤0.01%	3024
2017 Q1	$454K	Sell	79,707 -3,626	-4%	-$23K	﹤0.01%	2821
2016 Q4	$607K	Sell	83,333 -22,053	-21%	-$138K	﹤0.01%	2770
2016 Q3	$844K	Buy	105,386 +8,418	+9%	+$77.3K	﹤0.01%	2622
2016 Q2	$876K	Sell	96,968 -10,299	-10%	-$96.8K	﹤0.01%	2581
2016 Q1	$866K	Sell	107,267 -3,288	-3%	-$23.7K	﹤0.01%	2552
2015 Q4	$1.2M	Hold	110,555	–	–	﹤0.01%	2479
2015 Q3	$897K	Sell	110,555 -7,274	-6%	-$114K	﹤0.01%	2625
2015 Q2	$2.85M	Buy	117,829 +14,724	+14%	+$465K	﹤0.01%	2072
2015 Q1	$4.34M	Sell	103,105 -2,568	-2%	-$102K	﹤0.01%	1739
2014 Q4	$3.56M	Sell	105,673 -3,927	-4%	-$111K	﹤0.01%	1865
2014 Q3	$2.69M	Sell	109,600 -2,512	-2%	-$70.6K	﹤0.01%	2042
2014 Q2	$3.3M	Buy	112,112 +6,725	+6%	+$215K	﹤0.01%	1977
2014 Q1	$4.64M	Sell	105,387 -2,780	-3%	-$122K	﹤0.01%	1672
2013 Q4	$4.14M	Hold	108,167	–	–	﹤0.01%	1778
2013 Q3	$2.37M	Sell	108,167 -1,241	-1%	-$24.4K	﹤0.01%	2099
2013 Q2	$1.91M	Buy	+109,408	New	+$1.92M	﹤0.01%	2202

Other funds holding LAB

EIP

Easterly Investment Partners Beverly, Massachusetts $1.97B AUM 25.87% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Russell Investments Group London, United Kingdom $114B AUM 41.71% 1-Year Est. Return

Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

TIAA CREF Investment Management's LAB Position: Q1 2019 in Review

TIAA CREF Investment Management increased its Standard BioTools (LAB) stake by 103% in Q1 2019, buying an estimated $746K and bringing the position to 139,397 shares worth $1.85M. The position accounts for ﹤0.01% of the portfolio, ranked #2042.

TIAA CREF Investment Management first reported a position in LAB in Q2 2013 and has held it in 24 quarters since. The position peaked at $4.64M in Q1 2014. 131 funds tracked by Wall St. Rank hold LAB as of Q1 2019.

TIAA CREF Investment Management held 139,397 shares of Standard BioTools worth $1.85M as of Q1 2019.
TIAA CREF Investment Management bought 70,793 Standard BioTools shares in Q1 2019, an estimated $746K.
Standard BioTools made up ﹤0.01% of TIAA CREF Investment Management's portfolio in Q1 2019, its #2042 holding.
TIAA CREF Investment Management first reported a position in Standard BioTools in Q2 2013 and has held it in 24 quarters since.
TIAA CREF Investment Management's Standard BioTools position peaked at $4.64M in Q1 2014.
131 funds tracked by Wall St. Rank held Standard BioTools as of Q1 2019.

Based on TIAA CREF Investment Management's 13F filing for Q1 2019, filed 14 May 2019.